| BCR/ABL activates mdm2 mRNA translation via the La antigen R Trotta, T Vignudelli, O Candini, RV Intine, L Pecorari, C Guerzoni, ... Cancer cell 3 (2), 145-160, 2003 | 272 | 2003 |
| Decorin is a novel antagonistic ligand of the Met receptor S Goldoni, A Humphries, A Nyström, S Sattar, RT Owens, DJ McQuillan, ... Journal of Cell Biology 185 (4), 743-754, 2009 | 259 | 2009 |
| Genetic evidence for the coordinated regulation of collagen fibrillogenesis in the cornea by decorin and biglycan G Zhang, S Chen, S Goldoni, BW Calder, HC Simpson, RT Owens, ... Journal of Biological Chemistry 284 (13), 8888-8897, 2009 | 255 | 2009 |
| Decorin evokes protracted internalization and degradation of the epidermal growth factor receptor via caveolar endocytosis JX Zhu, S Goldoni, G Bix, RT Owens, DJ McQuillan, CC Reed, RV Iozzo Journal of Biological Chemistry 280 (37), 32468-32479, 2005 | 224 | 2005 |
| Decorin protein core inhibits in vivo cancer growth and metabolism by hindering epidermal growth factor receptor function and triggering apoptosis via caspase-3 activation DG Seidler, S Goldoni, C Agnew, C Cardi, ML Thakur, RT Owens, ... Journal of Biological Chemistry 281 (36), 26408-26418, 2006 | 222 | 2006 |
| Tumor microenvironment: Modulation by decorin and related molecules harboring leucine‐rich tandem motifs S Goldoni, RV Iozzo International journal of cancer 123 (11), 2473-2479, 2008 | 202 | 2008 |
| An antimetastatic role for decorin in breast cancer S Goldoni, DG Seidler, J Heath, M Fassan, R Baffa, ML Thakur, RT Owens, ... The American journal of pathology 173 (3), 844-855, 2008 | 187 | 2008 |
| Cell-geometry-dependent changes in plasma membrane order direct stem cell signalling and fate TC von Erlach, S Bertazzo, MA Wozniak, CM Horejs, SA Maynard, ... Nature materials 17 (3), 237-242, 2018 | 184 | 2018 |
| Biologically active decorin is a monomer in solution S Goldoni, RT Owens, DJ McQuillan, Z Shriver, R Sasisekharan, DE Birk, ... Journal of biological chemistry 279 (8), 6606-6612, 2004 | 140 | 2004 |
| A soluble ectodomain of LRIG1 inhibits cancer cell growth by attenuating basal and ligand-dependent EGFR activity S Goldoni, RA Iozzo, P Kay, S Campbell, A McQuillan, C Agnew, JX Zhu, ... Oncogene 26 (3), 368-381, 2007 | 126 | 2007 |
| Combinations with allosteric SHP2 inhibitor TNO155 to block receptor tyrosine kinase signaling C Liu, H Lu, H Wang, A Loo, X Zhang, G Yang, C Kowal, S Delach, ... Clinical Cancer Research 27 (1), 342-354, 2021 | 122 | 2021 |
| Proepithelin regulates prostate cancer cell biology by promoting cell growth, migration, and anchorage-independent growth G Monami, V Emiliozzi, A Bitto, F Lovat, SQ Xu, S Goldoni, M Fassan, ... The American journal of pathology 174 (3), 1037-1047, 2009 | 91 | 2009 |
| Small leucine-rich proteoglycans RV Iozzo, S Goldoni, AD Berendsen, MF Young The extracellular matrix: an overview, 197-231, 2011 | 60 | 2011 |
| Functionalized Poly(γ‐Glutamic Acid) Fibrous Scaffolds for Tissue Engineering C Gentilini, Y Dong, JR May, S Goldoni, DE Clarke, BH Lee, ET Pashuck, ... Advanced healthcare materials 1 (3), 308-315, 2012 | 53 | 2012 |
| A central role for decorin during vertebrate convergent extension JJ Zoeller, W Pimtong, H Corby, S Goldoni, AE Iozzo, RT Owens, SY Ho, ... Journal of Biological Chemistry 284 (17), 11728-11737, 2009 | 50 | 2009 |
| MITOSTATIN, a putative tumor suppressor on chromosome 12q24. 1, is downregulated in human bladder and breast cancer A Vecchione, M Fassan, V Anesti, A Morrione, S Goldoni, G Baldassarre, ... Oncogene 28 (2), 257-269, 2009 | 50 | 2009 |
| SHP2 blockade enhances anti-tumor immunity via tumor cell intrinsic and extrinsic mechanisms Y Wang, M Mohseni, A Grauel, JE Diez, W Guan, S Liang, JE Choi, M Pu, ... Scientific reports 11 (1), 1399, 2021 | 48 | 2021 |
| Enzymatically cross‐linked gelatin/chitosan hydrogels: tuning gel properties and cellular response MA Da Silva, F Bode, AF Drake, S Goldoni, MM Stevens, CA Dreiss Macromolecular bioscience 14 (6), 817-830, 2014 | 47 | 2014 |
| Proepithelin is an autocrine growth factor for bladder cancer F Lovat, A Bitto, SQ Xu, M Fassan, S Goldoni, D Metalli, V Wubah, ... Carcinogenesis 30 (5), 861-868, 2009 | 47 | 2009 |
| Tumor intrinsic efficacy by SHP2 and RTK inhibitors in KRAS-mutant cancers HX Hao, H Wang, C Liu, S Kovats, R Velazquez, H Lu, B Pant, M Shirley, ... Molecular cancer therapeutics 18 (12), 2368-2380, 2019 | 45 | 2019 |
